Magnolol induces apoptosis in vascular smooth muscle

Jiun H. Chen, Chin Chen Wu, George Hsiao, Mao Hsiung Yen

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Magnolol, an active component extracted from Magnolia officinalis, has various pharmacological effects, including potent antioxidant activity. In the present study, we investigated the effect of magnolol on apoptosis in rat vascular smooth muscle cells (VSMCs), using terminal-deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate nick end labelling (TUNEL) and flow cytometric analysis. Magnolol (5-20 μM) concentration-dependently induced significant VSMC apoptosis, this effect being blocked by the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk, 50 μM). To study the molecular mechanism, the mitochondrial death pathway was examined. Magnolol increased caspase-3 and caspase-9 activities significantly and reduced the mitochondrial potential (ΔΨm). The levels of B-cell leukaemia/lymphoma-2 (Bcl-2), but not those of Bcl-2-associated X protein (Bax) or Bcl-XL, were down-regulated concentration dependently by magnolol. In an animal model, balloon angioplasty-induced neointima formation was inhibited significantly by magnolol and Bcl-2 protein levels were reduced. Taken together, these results show that magnolol induces apoptosis in VSMCs via the mitochondrial death pathway. This effect is mediated through down-regulation of Bcl-2 protein levels, both in vivo and in vitro. Magnolol thus shows potential as a novel therapeutic agent for the treatment of atherosclerosis and re-stenosis.

Original languageEnglish
Pages (from-to)127-133
Number of pages7
JournalNaunyn-Schmiedeberg's Archives of Pharmacology
Volume368
Issue number2
DOIs
Publication statusPublished - Aug 1 2003

Fingerprint

Vascular Smooth Muscle
B-Cell Leukemia
Apoptosis
B-Cell Lymphoma
Smooth Muscle Myocytes
Magnolia
Neointima
bcl-2-Associated X Protein
Caspase Inhibitors
Balloon Angioplasty
DNA Nucleotidylexotransferase
magnolol
Caspase 9
Caspase 3
Atherosclerosis
Pathologic Constriction
Proteins
Down-Regulation
Animal Models
Antioxidants

Keywords

  • Aorta
  • Apoptosis
  • Bcl-2
  • Caspase
  • Magnolol
  • Rat
  • Re-stenosis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Magnolol induces apoptosis in vascular smooth muscle. / Chen, Jiun H.; Wu, Chin Chen; Hsiao, George; Yen, Mao Hsiung.

In: Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 368, No. 2, 01.08.2003, p. 127-133.

Research output: Contribution to journalArticle

Chen, Jiun H. ; Wu, Chin Chen ; Hsiao, George ; Yen, Mao Hsiung. / Magnolol induces apoptosis in vascular smooth muscle. In: Naunyn-Schmiedeberg's Archives of Pharmacology. 2003 ; Vol. 368, No. 2. pp. 127-133.
@article{635271eb927842a88ba4344478759488,
title = "Magnolol induces apoptosis in vascular smooth muscle",
abstract = "Magnolol, an active component extracted from Magnolia officinalis, has various pharmacological effects, including potent antioxidant activity. In the present study, we investigated the effect of magnolol on apoptosis in rat vascular smooth muscle cells (VSMCs), using terminal-deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate nick end labelling (TUNEL) and flow cytometric analysis. Magnolol (5-20 μM) concentration-dependently induced significant VSMC apoptosis, this effect being blocked by the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk, 50 μM). To study the molecular mechanism, the mitochondrial death pathway was examined. Magnolol increased caspase-3 and caspase-9 activities significantly and reduced the mitochondrial potential (ΔΨm). The levels of B-cell leukaemia/lymphoma-2 (Bcl-2), but not those of Bcl-2-associated X protein (Bax) or Bcl-XL, were down-regulated concentration dependently by magnolol. In an animal model, balloon angioplasty-induced neointima formation was inhibited significantly by magnolol and Bcl-2 protein levels were reduced. Taken together, these results show that magnolol induces apoptosis in VSMCs via the mitochondrial death pathway. This effect is mediated through down-regulation of Bcl-2 protein levels, both in vivo and in vitro. Magnolol thus shows potential as a novel therapeutic agent for the treatment of atherosclerosis and re-stenosis.",
keywords = "Aorta, Apoptosis, Bcl-2, Caspase, Magnolol, Rat, Re-stenosis",
author = "Chen, {Jiun H.} and Wu, {Chin Chen} and George Hsiao and Yen, {Mao Hsiung}",
year = "2003",
month = "8",
day = "1",
doi = "10.1007/s00210-003-0779-3",
language = "English",
volume = "368",
pages = "127--133",
journal = "Naunyn-Schmiedeberg's Archives of Pharmacology",
issn = "0028-1298",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Magnolol induces apoptosis in vascular smooth muscle

AU - Chen, Jiun H.

AU - Wu, Chin Chen

AU - Hsiao, George

AU - Yen, Mao Hsiung

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Magnolol, an active component extracted from Magnolia officinalis, has various pharmacological effects, including potent antioxidant activity. In the present study, we investigated the effect of magnolol on apoptosis in rat vascular smooth muscle cells (VSMCs), using terminal-deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate nick end labelling (TUNEL) and flow cytometric analysis. Magnolol (5-20 μM) concentration-dependently induced significant VSMC apoptosis, this effect being blocked by the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk, 50 μM). To study the molecular mechanism, the mitochondrial death pathway was examined. Magnolol increased caspase-3 and caspase-9 activities significantly and reduced the mitochondrial potential (ΔΨm). The levels of B-cell leukaemia/lymphoma-2 (Bcl-2), but not those of Bcl-2-associated X protein (Bax) or Bcl-XL, were down-regulated concentration dependently by magnolol. In an animal model, balloon angioplasty-induced neointima formation was inhibited significantly by magnolol and Bcl-2 protein levels were reduced. Taken together, these results show that magnolol induces apoptosis in VSMCs via the mitochondrial death pathway. This effect is mediated through down-regulation of Bcl-2 protein levels, both in vivo and in vitro. Magnolol thus shows potential as a novel therapeutic agent for the treatment of atherosclerosis and re-stenosis.

AB - Magnolol, an active component extracted from Magnolia officinalis, has various pharmacological effects, including potent antioxidant activity. In the present study, we investigated the effect of magnolol on apoptosis in rat vascular smooth muscle cells (VSMCs), using terminal-deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate nick end labelling (TUNEL) and flow cytometric analysis. Magnolol (5-20 μM) concentration-dependently induced significant VSMC apoptosis, this effect being blocked by the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk, 50 μM). To study the molecular mechanism, the mitochondrial death pathway was examined. Magnolol increased caspase-3 and caspase-9 activities significantly and reduced the mitochondrial potential (ΔΨm). The levels of B-cell leukaemia/lymphoma-2 (Bcl-2), but not those of Bcl-2-associated X protein (Bax) or Bcl-XL, were down-regulated concentration dependently by magnolol. In an animal model, balloon angioplasty-induced neointima formation was inhibited significantly by magnolol and Bcl-2 protein levels were reduced. Taken together, these results show that magnolol induces apoptosis in VSMCs via the mitochondrial death pathway. This effect is mediated through down-regulation of Bcl-2 protein levels, both in vivo and in vitro. Magnolol thus shows potential as a novel therapeutic agent for the treatment of atherosclerosis and re-stenosis.

KW - Aorta

KW - Apoptosis

KW - Bcl-2

KW - Caspase

KW - Magnolol

KW - Rat

KW - Re-stenosis

UR - http://www.scopus.com/inward/record.url?scp=0041375666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041375666&partnerID=8YFLogxK

U2 - 10.1007/s00210-003-0779-3

DO - 10.1007/s00210-003-0779-3

M3 - Article

C2 - 12898128

AN - SCOPUS:0041375666

VL - 368

SP - 127

EP - 133

JO - Naunyn-Schmiedeberg's Archives of Pharmacology

JF - Naunyn-Schmiedeberg's Archives of Pharmacology

SN - 0028-1298

IS - 2

ER -